- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00049452
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
A Randomized, Placebo Controlled Trial Of Zoledronic Acid For The Prevention Of Bone Loss In Premenopausal Women With Early Stage Breast Cancer
RATIONALE: It is not yet known whether zoledronate is effective in preventing bone loss in premenopausal women who are receiving adjuvant chemotherapy after undergoing surgery for early stage breast cancer.
PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate in preventing bone loss in premenopausal women who are receiving chemotherapy after surgery for early stage breast cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
- Compare the changes in bone mineral density (BMD) and bone turnover that occur in premenopausal women with resected early stage breast cancer during and after 6 months of adjuvant chemotherapy.
- Determine the factors that predict bone loss during chemotherapy, particularly induction of amenorrhea, type of chemotherapeutic regimen, glucocorticoid exposure, and baseline BMD, in these patients.
- Determine whether zoledronate prevents bone loss in these patients when given during and after adjuvant chemotherapy.
- Determine the effect of zoledronate on markers of bone turnover in these patients during and after adjuvant chemotherapy.
- Determine whether the effect on markers of bone turnover predicts response to zoledronate in these patients.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to estrogen receptor status (positive vs negative), progesterone receptor status (positive vs negative), and adjuvant chemotherapy regimen. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive zoledronate IV over 15 minutes on day 1.
- Arm II: Patients receive placebo IV over 15 minutes on day 1. In both arms, treatment repeats every 3 months for up to 4 courses in the absence of disease progression. Patients also receive calcium and cholecalciferol (vitamin D) supplements daily.
Quality of life is assessed at baseline and at 6 and 12 months.
Patients are followed at 1 year.
PROJECTED ACCRUAL: A total of 120 patients (60 per treatment arm) will be accrued for this study.
Type d'étude
Inscription (Anticipé)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Connecticut
-
Stamford, Connecticut, États-Unis, 06904
- Carl and Dorothy Bennett Cancer Center at Stamford Hospital
-
-
New Jersey
-
Paramus, New Jersey, États-Unis, 07652-2509
- Valley Hospital - Paramus
-
-
New York
-
New York, New York, États-Unis, 10032
- Herbert Irving Comprehensive Cancer Center at Columbia University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Diagnosis of localized breast cancer
- Stage I or II (T1-3, N0-2, M0)
- Planned adjuvant chemotherapy (after surgery) of at least 6 months in duration
Hormone receptor status:
- Estrogen receptor and progesterone receptor status known
PATIENT CHARACTERISTICS:
Age
- 18 to 50
Sex
- Female
Menopausal status
- Premenopausal or perimenopausal
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Creatinine less than 2 mg/dL
Other
- No T score of less than 2.0 on bone mineral density (BMD)
- No fragility fracture
- No lumbar spine anatomy that would preclude accurate BMD measurement of a minimum of 3 lumbar vertebrae
- Not pregnant
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- Not specified
Radiotherapy
- No concurrent radiotherapy
Surgery
- See Disease Characteristics
Other
- At least 1 month since prior calcitonin
- At least 12 months since prior bisphosphonates given for more than 1 month duration
- No concurrent fluoride therapy (10 mg/day or more)
- No concurrent enrollment in another experimental drug study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Masquage: Double
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
|---|
|
Changes in lumbar spine bone mineral density (BMD) at 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
|---|
|
Changes in lumbar spine BMD at 12 and 24 months
|
|
Total hip and femoral neck BMD at 6, 12, and 24 months
|
|
Serum markers of bone turnover (osteocalcin, bone-specific alkaline phosphatase, and cross-linked C-telopeptide of type 1 collagen levels) measured every 6 weeks for 6 months, and at 9 and 12 months
|
|
Quality of life as measured by the Short Form-36 instrument at baseline, and at 6 and 12 months
|
|
Frais de traitement
|
Collaborateurs et enquêteurs
Collaborateurs
Publications et liens utiles
Publications générales
- Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, Awad D, Shane E. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab. 2010 Feb;95(2):559-66. doi: 10.1210/jc.2009-1366. Epub 2009 Dec 18.
- Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008 Oct 10;26(29):4739-45. doi: 10.1200/JCO.2008.16.4707. Epub 2008 Aug 18.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000258105
- CPMC-IRB-14069
- NCI-G02-2127
- NOVARTIS-CPMC-IRB-14069
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .